Anaphylactic reactions to biological drugs.
Sign Up to like & getrecommendations! Published in 2020 at "Current Opinion in Allergy and Clinical Immunology"
DOI: 10.1097/aci.0000000000000666
Abstract: PURPOSE OF REVIEW This review summarizes the current knowledge of the pathogenic mechanisms of biologics-induced anaphylaxis, and the diagnostic and prophylactic strategies in the management of potentially reactive patients, to improve the safety profile of… read more here.
Keywords: biological drugs; anaphylactic reactions; immunology; antidrug antibodies ... See more keywords
Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death‐1 therapies and lessons learned from natalizumab
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Dermatology"
DOI: 10.1111/bjd.19137
Abstract: We read with interest the BJD online publication by Gambichler and colleagues1 about a decline of programmed death (PD)-1+ circulating T regulatory cells (Tregs) predicting clinical outcome in anti-PD-1 therapy. The study highlights the potential… read more here.
Keywords: death; immune monitoring; neutralizing antidrug; competition neutralizing ... See more keywords
Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove
Sign Up to like & getrecommendations! Published in 2023 at "JCI Insight"
DOI: 10.1172/jci.insight.156643
Abstract: Targeted biologic therapies can elicit an undesirable host immune response characterized by the development of antidrug antibodies (ADA), an important cause of treatment failure. The most widely used biologic across immune-mediated diseases is adalimumab, a… read more here.
Keywords: antidrug antibodies; development antidrug; development; hla peptide ... See more keywords
Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Society of Nephrology : JASN"
DOI: 10.1681/asn.2018030329
Abstract: Fabry disease (FD) is an X-linked lysosomal storage disorder (LSD) caused by mutations of the α-galactosidase A gene. The lysosomal enzyme α -galactosidase A (GLA) mediates the hydrolysis of the terminal α -galactosyl moiety from… read more here.
Keywords: replacement therapy; therapy antidrug; effects enzyme; enzyme replacement ... See more keywords